IFI16 and synovial sarcoma: In contrast to SLE, anti-IFI16 was not enriched in patients with anti-AIM2 antibodies in SS (35% anti-AIM2-positive and anti-IFI16-positive versus 28% anti-AIM2-negative and anti-IFI16-positive in SS, P = 0.4324), showing that the association between anti-IFI16 and anti-AIM2 antibodies is specific to SLE, where these immune responses are also associated with anti-dsDNA antibodies.